Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers

2004 ◽  
Vol 44 (9) ◽  
pp. 991-1002 ◽  
Author(s):  
Rohini Ramakrishnan ◽  
Wing K. Cheung ◽  
Mary C. Wacholtz ◽  
Neil Minton ◽  
William J. Jusko
Keyword(s):  
Healthy Volunteers ◽  
Recombinant Human Erythropoietin ◽  
Pharmacodynamic Modeling ◽  
Human Erythropoietin ◽  
Single And Multiple Doses ◽  
Multiple Doses

scholarly journals Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers

2016 ◽  
Vol 38 (1) ◽  
pp. 53-65 ◽  
Author(s):  
Randall Hoover ◽  
Thomas Hunt ◽  
Michael Benedict ◽  
Susan K. Paulson ◽  
Laura Lawrence ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Single And Multiple Doses ◽  
Multiple Doses ◽  
Pharmacokinetic Properties

scholarly journals Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers

Blood ◽  
1990 ◽  
Vol 76 (9) ◽  
pp. 1718-1722 ◽  
Author(s):  
FG McMahon ◽  
R Vargas ◽  
M Ryan ◽  
AK Jain ◽  
RI Abels ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Controlled Study ◽  
Normal Male ◽  
Double Blind ◽  
Subcutaneous Injections ◽  
Human Erythropoietin ◽  
Multiple Doses ◽  
Adverse Experiences ◽  
Clinically Significant ◽  
Male Subjects

A double-blind, placebo-controlled study of the pharmacokinetics and safety of multiple doses of recombinant human erythropoietin [rHuEPO 150 or 300 U/kg either by intravenous (IV) bolus or subcutaneously (SC)] in normal male subjects demonstrated that rHuEPO had a dose- related effect on the hematocrit independent of the route of administration and that multiple doses of rHuEPO had no direct pressor effects. When rHuEPO was injected IV, a monoexponential decrease in serum EPO level was evident for 18 to 24 hours postdose. Absorption of SC injected rHuEPO occurred more slowly, with relatively low serum EPO levels being maintained for 48 hours. All rHuEPO antibody titer determinations were negative. With the exception of significant increases in hemoglobin and hematocrit, no clinically significant changes occurred. No hypertensive, convulsive, or thrombotic events were observed. Of the adverse experiences observed in 10 subjects, none was considered clinically significant, and none of the subjects dropped out because of adverse experiences.

scholarly journals Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers

2021 ◽  
Vol 17 (S9) ◽  
Author(s):  
William Kielbasa ◽  
Sergey Shcherbinin ◽  
Paul Goldsmith ◽  
Krista M Phipps ◽  
Kevin Biglan ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Single And Multiple Doses ◽  
Multiple Doses ◽  
Brain Target

Hypokalaemia in Healthy Volunteers after Single and Multiple Doses of Formoterol or Salbutamol

1998 ◽  
Vol 15 (6) ◽  
pp. 523-529 ◽  
Author(s):  
BTJ van den Berg ◽  
RT Louwerse ◽  
GJHM Luiken ◽  
RE Jonkers ◽  
CJ van Boxtel
Keyword(s):  
Healthy Volunteers ◽  
Single And Multiple Doses ◽  
Multiple Doses

Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers

2012 ◽  
Vol 52 (2) ◽  
pp. 195-203 ◽  
Author(s):  
SeungHwan Lee ◽  
Bo-Hyung Kim ◽  
Won-Seok Nam ◽  
Seo Hyun Yoon ◽  
Joo-Youn Cho ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Single And Multiple Doses ◽  
Multiple Doses ◽  
Cyp2c19 Polymorphism
Sign in / Sign up

Export Citation Format

Share Document